CHJ.91157
Lysostaphin from Staphylococcus staphylolyticus
--
--
Ordering
Available Variants1 mg
CHJ.91157-1mg
Price
€140.00
Available – Dispatch in 14 days
5 mg
CHJ.91157-5mg
Price
€544.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mg | CHJ.91157-1mg | €140.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHJ.91157-5mg | €544.00 |
≥500 units/mg protein, lyophilized powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| CAS Number | 9011-93-2 |
|---|---|
| UNSPSC Code | 12352204 |
| NACRES | NA.54 |
| EC Number | 3.4.24.75 (BRENDA, IUBMB) |
| MDL number | MFCD00131556 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS08
|
|---|---|
| signalword | Danger |
| hcodes | H334 |
| pcodes | P261 - P284 - P304 + P340 + P312 - P501 |
| Hazard Classifications | Resp. Sens. 1 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
Lysostaphin, a glycylglycine endopeptidase, is an enzyme derived from Staphylococcus staphylolyticus, with a CAS number of 9011-93-2. This bacteriolytic enzyme specifically targets and cleaves the pentaglycine crosslinks in the peptidoglycan layer of Staphylococcus cell walls, ultimately leading to cell lysis. Lysostaphin has been shown to exhibit potent antimicrobial activity against a range of Staphylococcus species, including methicillin-resistant Staphylococcus aureus. The enzymes unique mechanism of action and specificity make it an attractive candidate for the development of novel antimicrobial therapies, particularly in the treatment of infections caused by multidrug-resistant Staphylococcus strains. Further research is needed to fully explore the therapeutic potential of lysostaphin and to investigate its potential applications in clinical settings. The enzymes properties and activities are being studied to understand its role in combating Staphylococcus infections.
